INDV Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Indivior Pharmaceuticals Inc (INDV) following the 2026 Q2 hedge fund 13F filings?

As of today, INDV has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), INDV gained -4.9% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Indivior Pharmaceuticals Inc (INDV)

286 + Investors. Track Smart Money conviction in INDV. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — INDV

Based on 288 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 11 quarters in a row

last 6Q

For 11 consecutive quarters, more hedge funds added INDV than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

288 hedge funds hold INDV right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +155% more funds vs a year ago

fund count last 6Q

+175 new funds entered over the past year (+155% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟡

Slight buying edge — 56% buying

180 buying140 selling

Last quarter: 180 funds bought or added vs 140 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

⚠️

Fewer new buyers each quarter (-6 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 39 → 91 → 90 → 84. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔄

Mostly new holders — 59% entered in last year

■ 15% conviction (2yr+) ■ 26% medium ■ 59% new

Only 42 funds (15%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

💎

Buying through price weakness — shares -2%, value -19%

Value

-19%

-2%

Last quarter: funds added -2% more shares while total portfolio value only changed -19%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.

📈

Growing discovery — still being found

24 → 39 → 91 → 90 → 84 new funds/Q

New funds entering each quarter: 39 → 91 → 90 → 84. A growing number of institutions are discovering INDV each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

🌱

Early stage — 66% of holders entered in last year

■ 19% veterans ■ 15% 1-2yr ■ 66% new

Of 294 current holders: 194 (66%) entered in the past year, only 56 (19%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.

🏆

Elite ownership — 51% AUM from top-100 funds

51% from top-100 AUM funds

54 of 286 holders are among the 100 largest funds by AUM, controlling 51% of total institutional value in INDV. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

6.3

out of 10

Moderate Exit Risk

Exit risk score 6.3/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	286	256	11.72%
13F Shares	121M	124M	-2.37%
Total Value	$3.57B	$4.43B	-19.36%
New Positions	82	90	-8
Increased Positions	93	81	+12
Closed Positions	52	27	+25
Reduced Positions	86	67	+19
Total Calls	4	8	-50.0%
Total Puts	3	3	-
PUT/CALL Ratio	0.75	0.38	Neutral

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

286

256

11.72%

13F Shares

121M

124M

-2.37%

Total Value

$3.57B

$4.43B

-19.36%

New Positions

-8

Increased Positions

+12

Closed Positions

+25

Reduced Positions

+19

Total Calls

-50.0%

Total Puts

PUT/CALL Ratio

0.75

0.38

Neutral

Institutional Holders (2026 Q2)

286 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in INDV. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 INDV holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Mangrove Partners IM, LLC	7.22%	2,676,730	$109.8M
2	Newtyn Management, LLC	6.69%	1,305,795	$53.6M
3	Madison Avenue Partners, LP	5.08%	2,874,368	$117.9M
4	Alta Fundamental Advisers LLC	4.98%	404,529	$16.6M
5	Oaktree Capital Management LP	3.49%	6,127,212	$251.4M
6	Two Seas Capital LP	2.83%	3,479,493	$142.8M
7	Melqart Asset Management (UK) Ltd	2.29%	585,664	$24.0M
8	Sandro Wealth Management LLC	2.18%	73,634	$3.0M
9	Stonepine Capital Management, LLC	1.92%	100,000	$4.1M
10	Parkman Healthcare Partners LLC	1.53%	364,269	$14.9M
11	Soleus Capital Management, L.P.	1.50%	1,064,000	$43.7M
12	PFM Health Sciences, LP	1.41%	401,208	$16.5M
13	Clark Estates Inc/Ny	0.87%	92,300	$3.8M
14	Deerfield Management Company, L.P.	0.71%	1,648,895	$67.7M
15	Oberweis Asset Management Inc/	0.66%	779,188	$32.0M
16	Navellier & Associates Inc	0.57%	173,860	$7.1M
17	Florida Financial Advisors, LLC	0.56%	80,891	$3.3M
18	Divisadero Street Capital Management, LP	0.56%	601,863	$24.7M
19	Driehaus Capital Management LLC	0.55%	2,299,054	$94.3M
20	Fuller & Thaler Asset Management, INC.	0.52%	4,615,816	$189.4M
21	Rock Springs Capital Management LP	0.49%	245,500	$10.1M
22	LightSquare Wealth Management, LLC	0.42%	15,000	$615K
23	Hennion & Walsh Asset Management, Inc.	0.42%	360,245	$14.8M
24	Integrated Quantitative Investments LLC	0.41%	61,555	$2.5M
25	Gendell Jeffrey L	0.40%	1,096,343	$45.0M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Indivior Pharmaceuticals Inc (INDV)

What does the Smart Money Trend signal show for INDV?

Buying streak — 11 quarters in a row: For 11 consecutive quarters, more hedge funds added INDV than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for INDV?

Slight buying edge — 56% buying: Last quarter: 180 funds bought or added vs 140 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for INDV holders?

Elite ownership — 51% AUM from top-100 funds: 54 of 286 holders are among the 100 largest funds by AUM, controlling 51% of total institutional value in INDV. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held INDV?

Mostly new holders — 59% entered in last year: Only 42 funds (15%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Indivior Pharmaceuticals Inc (INDV) following the 2026 Q2 hedge fund 13F filings?

As of today, INDV has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), INDV has gained -4.9% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Indivior Pharmaceuticals Inc (INDV)

Smart Money Signals — INDV

Buying streak — 11 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +155% more funds vs a year ago

Slight buying edge — 56% buying

Fewer new buyers each quarter (-6 vs last Q)

Mostly new holders — 59% entered in last year

Buying through price weakness — shares -2%, value -19%

Growing discovery — still being found

Early stage — 66% of holders entered in last year

Elite ownership — 51% AUM from top-100 funds

Institutional Sentiment Summary — INDV

Hedge Fund Ownership: INDV

Market Analysis: INDV

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: INDV

Is It Too Late to Buy Indivior Pharmaceuticals Inc (INDV) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: INDV

Statistics: INDV

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Indivior Pharmaceuticals Inc (INDV)

Welcome to 13Foresight!